License-out
<From LTT to other companies>

As a drug discovery-related bio-venture, we aim to license out our pipelines under development to other companies as early as possible. Some of them have already proceeded to phase II clinical trials, showing the POC. The followings are brief explanations about our pipelines under development. Please contact us, if you would like us to send you reference materials or you would like to meet us to get more information.

(1) PC-SOD as a therapeutic agent for myocardial infarction, stroke, and ARDS

As explained in the other section, PC-SOD, which can remove reactive oxygen species, an underlying cause of many diseases effectively, is promising as a therapeutic agent for various diseases. In terms of idiopathic pulmonary fibrosis and ulcerative colitis, our phase II clinical trial actually indicates the efficacy of PC-SOD. The efficacy was demonstrated in animal models with a wide variety of diseases, such as COPD, dry mouth, myocardial infarction, spinal code injury, heat injury, traumatic brain damage, and disability at transplant, well as these diseases, stroke, scleroderma, or ARDS. We can license our substance patent and use patent in terms of all of these diseases. And we are also pleased to work with you in collaborative development. Focusing on myocardial infarction, stroke, and ARDS, clinical trials targeted for these diseases are being prepared. We hope to license the patent for the substance or to collaborate with partners in drug development related to these diseases.

【drug】LT-1001 (iv), LT-1002 (inhalation) (PC-SOD)
【target disease】stroke, myocardial infarction, ARDS, ulcerative colitis, idiopathic pulmonary fibrosis and so on
【stage】phase I clinical study being completed; phase II clinical study for some of target diseases being completed
【IP】substance patent, use patents, formulation patent

(2) Stealth-type polymeric nanoparticles, a DDS carrier characterized by accumulation and sustained-release

Unlike previous DDS carriers characterized by either accumulation or sustained-release, we successfully developed the first stealth-type polymeric nanoparticles with both of these functions in the world. The following (3) and (4) describe examples of development with this technology. We also possess the patent for the particle itself and can offer collaborative development and research by encapsulating a drug you want to into the particle.

(3) Nano-PGE1 as a therapeutic agent for chronic artery occlusive disease

Having contributed to treatment for many patients, our lipo-PGE1 has a problem of QOL because it requires daily injections. Therefore, we developed nano-PGE1 that encapsulates PGE1 in a DDS carrier, stealth-type polymeric nanoparticles characterized by accumulation and sustained release. This product is expected to have higher effects by administration about every two weeks than that by daily administration of lipo-PGE1.

【drug】LT-2003 (Nano-PGE1)
【target disease】chronic artery occlusive disease
【stage】Non-Clinical study
【IP】substance and formulation patents

(4) Nano-BPS as a therapeutic agent for pulmonary hypertension

Currently, for treatment of pulmonary arterial hypertension, continuous PGI2 infusion via pump or oral administration of a PGI2 derivative are mainly used; however, the former and latter have problems of low QOL and low effect, respectively. Therefore, we developed the nano-BPS that encapsulates PGI2 derivative(BPS) in a DDS carrier, stealth-type polymeric nanoparticles characterized by accumulation, and sustained release. This product accumulates on the affected vascular site and releases PGI2  derivative, and it is expected to have sufficient effect by administration even every two weeks.

【drug】LT-2004 (Nano-BPS)
【target disease】pulmonary arterial hypertension
【stage】Non-Clinical study
【IP】substance and formulation patents

(5) New NSAID with less gastric ulcer and excellent in fast-acting

Nonsteroidal anti-inflammatory drugs (NSAIDs) are clinically essential as antipyretic analgesics, but NSAID-related gastric ulcers have become a big problem. A new NSAID we discovered (LT-3001) is much less likely to develop gastric ulcers and has a more fast-acting effect compared to existing NSAIDs. We hope to license the patent for the substance as soon as possible.

【drug】LT-3001 (new chemical)
【target disease】Inflammatory disease
【stage】Non-Clinical study
【IP】substance patent

(6) Therapeutic agent for COPD with long-acting bronchodilatory and anti-inflammatory effects (new chemical)

In the current treatment of patients with COPD, a long-acting bronchodilator for improvement of symptoms and steroid therapy for delay of disease progression are mainly used. LT-3002, which we discovered, has a longer bronchodilatory effect than existing bronchodilators and a stronger anti-inflammatory effect than steroids in animal experiments. We hope to license the substance patent for this promising new substance as a therapeutic agent for COPD.

【drug】LT-3002 (new chemical)
【target disease】COPD
【stage】Non-Clinical study
【IP】substance patent

(7) Therapeutic agent for COPD with bronchodilatory and anti-inflammatory effects (approved drug)

In the current treatment of patients with COPD, a long-acting bronchodilator for improvement of symptoms and steroid therapy for delayed disease progression are mainly used. We discovered LT-4001, an approved drug with bronchodilatory and anti-inflammatory effects from our approved drug library and hope to license the use patent for this substance along with LT-3002 mentioned in the above (6).

【drug】LT-4001 (approved drug)
【target disease】COPD
【stage】Phase 1 clinical study has been completed
【IP】use patents, formulation patent

(8) Therapeutic agent for dry eye that works based on a new mechanism

Treatment for dry eye has not been established yet regardless of the launch and development of pharmaceutical drugs that work on various mechanisms. We focused attention on the fact that there is currently no drug to protect the cornea against injury from hyperosmolar tears and discovered the approved drug LT-4002, using our approved-drug library. LT-4002 showed the prominent effect in animal model of dry eye. Now the phase II clinical trial to confirm efficacy is being operated. In addition to LT-4002, we also discovered LT-4003, a different approved drug with a similar effect.

【drug】LT-4002、LT-4003 (approved drug)
【target disease】dry eye
【stage】Phase II clinical study is now operated.
【IP】use patents, formulation patent

(9) New therapeutic agent for functional dyspepsia for improvement of delayed gastric emptying and failed adaptive relaxation

Functional dyspepsia (FD) is a disease characterized by a heavy stomach feeling or gastric pain regardless of no organic changes. Fifteen to twenty percent of the population is said to have the disease, but no treatment has been established. FD (heavy stomach feeling) is caused by delayed gastric emptying and failed adaptive relaxation. We searched for a pharmaceutical drug to recover gastric emptying in animal models and finally discovered the approved drug LT-4005. LT-4005 recovered decreased adaptive relaxation due to immobilization stress with a similar effect as acotiamide. Therefore, LT-4005 is an effective agent for both delayed gastric emptying and failed adaptive relaxation, which play important roles in FD (heavy stomach feeling).

【drug】LT-4005(approved drug)
【target disease】FD
【stage】Phase 1 clinical study has been completed
【IP】use patents

(10) New therapeutic agent for IBS for improvement of stress-related diarrhea and visceral hypersensitivity

Irritable bowel syndrome (IBS) is a disease characterized by abnormal bowel habits or intestinal pain regardless of no organic changes. More than 10% of the population is said to have the disease, but no treatment has been established. We searched for a pharmaceutical drug to control psychological stress-induced bowels and visceral (intestinal) hypersensitivity in animal and finally discovered the approved drug LT-4006. Therefore, LT-4006 is an effective agent for both stress-induced bowels and visceral hypersensitivity, which play important roles in IBS characterized by stress-related diarrhea.

【drug】LT-4006 (approved drug)
【target disease】IBS
【stage】Phase 1 clinical study has been completed
【IP】use patents

(11) Therapeutic agent for neurodegenerative diseases through autophagy induction

Autophagy is a major mechanism of degradation of the cytosolic component with lysosome. Recent research has shown that autophagy selectively degrades the coagulable abnormal proteins that may cause neurodegenerative diseases (for example, Alzheimer's disease or polyglutamine disease) and prevent the accumulation and coagulation of the proteins. So, a drug that activates autophagy is expected to be a radical therapeutic agent for neurodegenerative diseases. Actually, results from many recent studies have supported this hypothesis. We worked collaboratively with Noboru Mizushima, professor at the University of Tokyo, who is an authority on autophagy research in mammals to search for pharmaceutical drugs that inhibit autophagy, and finally discovered LT-4007, multiple approved drugs.

【drug】LT-4007
【target disease】Neurodegenerative disease
【stage】Phase 1 clinical study has been completed
【IP】use patents

(12) Anticancer drug through autophagy inhibition

Autophagy is a major mechanism of degradation of the cytosolic component with lysosome. Recent research has shown that many cancer cells are largely dependent on autophagy to survive, and now, a drug that inhibits autophagy is emerging as a new type of anticancer drug. Actually, many clinical trials with chloroquine or hydroxychloroquine (autophagy inhibitor) have shown efficacy for various types of cancer. We worked collaboratively with Noboru Mizushima, professor at the University of Tokyo, who is an authority on autophagy research in mammals, to search for pharmaceutical drugs that inhibit autophagy, and finally discovered LT-4008, multiple approved drugs.

【drug】LT-4008
【target disease】Cancer
【stage】Phase 1 clinical study has been completed
【IP】use patents

Inquiry about collaborative development